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A B S T R A C T
Background
Bronchiolitis is a serious, potentially life-threatening respiratory illness commonly affecting young babies. It is most often caused by
Respiratory Syncytial Virus (RSV). Diagnosis is usually made on clinical grounds (especially tachypnoea and wheezing in a child less
than two years of age). Antibiotics are not recommended for bronchiolitis unless there is concern about complications such as secondary
bacterial pneumonia. Nevertheless, they are used at rates of 34 to 99% in uncomplicated cases.
Objectives
To evaluate the use of antibiotics for bronchiolitis.
Search strategy
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) which includes the Acute Respiratory Infection Groups’
specialized register, the Database of Abstracts of Reviews of Effects (DARE) (The Cochrane Library 2006, issue 3); MEDLINE (January
1966 to August Week 2, 2006); EMBASE (1990 to March 2006); and Current Contents (2001 to September 2006).
Selection criteria
Types of studies: single or double blind randomised controlled trials comparing antibiotics to placebo in the treatment of bronchiolitis.
Types of participants: children under the age of two years diagnosed with bronchiolitis using clinical criteria (including respiratory
distress preceded by coryzal symptoms with or without fever).
Types of interventions: oral, intravenous, intramuscular or inhaled antibiotics versus placebo.
Types of outcome measures: primary clinical outcomes: time for the resolution of symptoms/signs (pulmonary markers: respiratory
distress; wheeze; crepitations; oxygen saturation; and fever).
Secondary outcomes: hospital admissions; time to discharge from hospital; re-admissions; complications/adverse events developed; and
radiological findings.
Data collection and analysis
Data were analysed using Review Manager software, version 4.2.7.
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Main results
One study met our inclusion criteria. It randomised children presenting clinically with bronchiolitis to either ampicillin or placebo.
The main outcome measure was duration of illness and death. There was no significant difference between the two groups for length
of illness and there were no deaths in either group.
Authors’ conclusions
This review found no evidence to support the use of antibiotics for bronchiolitis. This results needs to be treated with caution given
only one RCT justified inclusion. It is unlikely that simple RCTs of antibiotics against placebo for bronchiolitis will be undertaken in
future. Research to identify a possible small subgroup of patients presenting with bronchiolitis-like symptoms who may benefit from
antibiotics may be justified. Otherwise, research may be better focused on determining the reasons for clinicians to use antibiotics so
readily for bronchiolitis, and ways of reducing their anxiety, and therefore their use of antibiotics for bronchiolitis.
P L A I N L A N G U A G E S U M M A R Y
Bronchiolitis is a common, potentially serious lung infection common in babies
Most cases are thought to be caused by a virus called Respiratory Syncytial Virus (RSV). It is themost common reason for hospitalisation
in babies under the age of six months. Despite its viral cause, antibiotics are prescribed in 34 to 99% of cases. This systematic review
found very little research on the effect of antibiotics on bronchiolitis. Only one trial was included comparing antibiotics with placebo.
It showed that antibiotics are no better than placebo at reducing the length of illness of bronchiolitis. Antibiotics need to be used
cautiously owing to potential for side effects, cost to the patient and the community and increasing bacterial resistance to antibiotics.
B A C K G R O U N D
Description of the condition
Bronchiolitis is a serious, potentially life threatening respiratory
illness that often affects young babies. It occurs most frequently
in the first year of life and is the commonest cause of hospital
admissions in infants under six months of age (Wohl 1978). The
most commonly identifiedpathogen isRespiratory Syncytial Virus
(RSV).Other viruses such as humanmeta-pneumovirus (HMPV),
influenza, parainfluenza, adenovirus and rhinovirus have also been
implicated (Williams 2004). Other less common pathogens in-
clude Mycoplasma pneumoniae (M. pneumoniae) which can occur
in sporadic outbreaks (Glezen 1971; Rose 1987).
Description of the intervention
The diagnosis is most often made on clinical grounds, which usu-
ally includes tachypnoea andwheezing in children under two years
of age (Bordley 2004). Immunofluorescence and culture of the
nasopharyngeal aspirate may be used to determine the causative
organism and may reduce antibiotic use (Christakis 2005). A
chest X-raymay showhyperinflation and patchy atelectasis (Smyth
2006). There are few effective therapies, including antiviral thera-
pies (Smyth 2006). Antibiotics are not recommended unless there
is concern for complications such as secondary bacterial pneumo-
nia (Fitzgerald 2004; Lozano 2002). This is based on evidence
suggesting a low risk of bacteremia (0.2%) in children with bron-
chiolitis and fever - a lower risk than for children with a fever
without a recognisable viral illness, where the rate ranges from 2 to
7% (Greenes 1999). Antibiotic use comes with significant harms
including common adverse reactions (rash, abdominal pain, di-
arrhoea and vomiting), cost and community bacterial resistance
(Brook 1998).
Infants with severe bronchiolitis requiring mechanical ventilation
have been shown to have high rates of bacterial co-infection. These
vary from 21% (Thorburn 2006) to 26% (Kyneber 2005) mea-
sured in both from endotracheal aspirates or in one infant, blood
culture. Consistent with these results, Kyneber 2005 reported an-
tibiotic use at 95% in infants with bronchiolitis in intensive care.
Antibiotics are commonly used, at rates of 34% (Vogel 2003),
45% (Christakis 2005; Thorburn 2006), 53% (Halna 2005) and
99% (Kabir 2003), prior to any ventilation.
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Why it is important to do this review
There are no published systematic reviews to inform the
widespread use of antibiotics for uncomplicated bronchiolitis.
O B J E C T I V E S
The objective of this review is to evaluate clinical outcomes result-
ing from the use of antibiotics for bronchiolitis in children com-
pared to placebo or other interventions.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Single or double blind randomised controlled trials comparing
antibiotics to placebo in the treatment of bronchiolitis.
Types of participants
Children under the age of two years who were defined as having
bronchiolitis using clinical criteria, including respiratory distress
preceded by coryzal symptoms with or without fever.
Types of interventions
Oral, intravenous, intramuscular or inhaled antibiotics versus
placebo.
Types of outcome measures
Primary outcomes
Time for the resolution of symptoms/signs
• pulmonary markers;
• respiratory distress;
• wheeze;
• crepitations;
• oxygen saturation; and
• fever.
Secondary outcomes
• Hospital admissions;
• time to discharge from hospital;
• re-admissions;
• complications/adverse events developed; and
• radiological findings.
Search methods for identification of studies
Electronic searches
We searched the following electronic databases: theCochraneCen-
tral Register of Controlled Trials (CENTRAL) which includes
the Acute Respiratory Infection Groups’ specialised register, the
Database of Abstracts of Reviews of Effects (DARE) (The Cochrane
Library 2006, issue 3); MEDLINE (January 1966 to AugustWeek
2, 2006); EMBASE (1990 toMarch 2006); and Current Contents
(2001 to September 2006).
Multiple strategies were used to identify as many trials as possible
that met the inclusion criteria, regardless of language or publica-
tion status. The following search terms, combined with the ap-
propriate methodological search filter (Dickersin 1994) were used
to search MEDLINE. These terms were modified to search CEN-
TRAL, DARE, EMBASE and Current Contents as required.
MEDLINE (OVID)
1 exp Bronchiolitis/
2 bronchiolit$.mp.
3 exp Respiratory Syncytial Viruses/
4 exp Respiratory Syncytial Virus Infections/
5 (respiratory syncytial virus$ or RSV$).mp.
6 or/1-5
7 exp Anti-Bacterial Agents/
8 antibiotic$.mp.
9 exp Macrolides/
10 (macrolide$ or azithromycin or clarithromycin or ery-
thromycin or roxithromycin or spiramycin).mp.
11 exp Cephalosporins/
12 (cephalosporin$ or cephalexin or cephaclor or cefaclor or ce-
fepime or cefotaxime or cephamycin$ or cefotetan or cefoxitin or
cefmetazole or cefpirome or cefpodoxime or ceftazidime or ceftri-
axone or cephamandole or cephazolin).mp.
13 exp Penicillins/
14 (penicillin$ or amoxicillin or amoxycillin or ampicillin or
benzylpenicillin or cloxacillin or dicloxacillin or flucloxacillin or
piperacillin or ticarcillin or sulbactam).mp.
15 exp Fluoroquinolones/
16 (fluoroquinolone$ or ciprofloxacin or enoxacin or norfloxacin
or ofloxacin or pefloxacin or fleroxacin or levofloxacin or moxi-
floxacin).mp.
17 exp Tetracycline/
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18 (tetracycline$ or doxycycline or methacycline or minocy-
cline).mp.
19 (amikacin or gentamicin or neomycin or netilmicin).mp.
20 (clindamycin or lincomycin).mp.
21 (chloramphenicol or amantadine or cotrimoxazole or trimetho-
prim).mp.
22 or/7-21
23 exp Child/
24 (children or infant$ or pediatric or paediatric).mp.
25 or/23-24
26 6 and 22 and 25
Searching other resources
All languages were considered. We hand searched the references of
all identified studies.One researcher and an expert librarian carried
out the search.We intended to contact experts in the field looking
for unpublished studies. However, the only included study came
from 1966 and authors were not contactable.
Data collection and analysis
Selection of studies
Database searching revealed the following results: 173 articles in
MEDLINE, 102 articles in EMBASE, 23 articles in CENTRAL
and two articles in DARE.
Two review authors independently scanned abstracts from the ini-
tial search results to identify trials that loosely meet the inclusion
criteria. Of these 300 articles, we rejected 298 on the basis of title
and abstract alone. The full text articles of the retrieved trials were
then reviewed by two authors and the inclusion criteria applied
independently (KF and GS). One study did not meet the inclu-
sion criteria as it did not use clinical criteria for inclusion in the
trial (Friis 1984). Two studies did meet the inclusion criteria (Field
1966, Mazumder 2006)
Data extraction and management
Two review authors (KF and GS) independently extracted data
from the chosen study using data extraction forms which included
type of intervention, adverse events, continuous and dichotomous
outcomes. We also noted the setting (hospital or primary care),
study population, any additional interventions/tests.
Assessment of risk of bias in included studies
Two review authors (KF, GS and JD) independently assessed each
study using the following criteria based on a published method
to assess the methodological quality (Chalmers 1990). Disagree-
ments were resolved by consensus. Studies were considered to be
of high quality and worthy of inclusion if they scored 6 out of 11
or more.
1. Method of treatment assignment
a. Correct, blinded, randomisation method described OR ran-
domised, double-blind statedANDgroup similarity documented.
b. Blinding and randomisation stated, but method not described
OR suspect technique, for example, envelope.
c. Randomisation claimed but not described, and investigator not
blinded.
d. Randomisation not mentioned.
2. Control of selection bias after treatment assignment
a. Intention to treat analysis AND full follow up.
b. Intention to treat analysis AND less than 15% loss to follow
up.
c. Analysis by treatment received only OR no mention of with-
drawals.
d. Analysis by treatment receivedANDnomention of withdrawals
ORmore than 15%withdrawals/ loss to follow up/ post-randomi-
sation exclusions.
3. Blinding
a. Blinding of (i) outcome assessor AND (ii) patient AND (iii)
care giver.
b. Blinding of (i) outcome assessor OR (patient AND care giver).
c. Blinding not done.
4. Outcome assessment
a. All patients had standardised assessment.
b. No standardised assessment OR not mentioned.
Unit of analysis issues
All data was analysed using Review Manager software, version
4.2.7. A sensitivity analysis and meta-analysis were not required.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
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Included studies
Field 1966 met the inclusion criteria as it used clinical selection
criteria and randomised children to ampicillin or placebo.
Excluded studies
Mazumder 2006 scored 3/11 on quality appraisal and was ex-
cluded. We discuss its results but they must be treated with cau-
tion. One study was excluded (Friis 1984) because it dealt with
both pneumonia and bronchiolitis using crepitations and radiog-
raphy as criteria for patient selection. It did perform a subgroup
analysis of the two groups (antibiotics and placebo) based on vi-
rological diagnosis and these results will be discussed.
Risk of bias in included studies
Studies were considered to be of high quality if they scored six or
more out of 11 according to the scale outlined in methods of the
review. Both review authors independently evaluated the included
study (Field 1966) and scored it 6 out of 11. Details of this can
be found in Table 1.
Effects of interventions
The results from the one included study are presented below (Field
1966). The characteristics of this study are tabled. It involved
randomising babies with the clinical presentation of bronchiolitis
to either placebo or ampicillin. The main outcome measure was
length of illness; this was found to be 9.54 days in the group re-
ceiving ampicillin and 9.7 days in the group receiving placebo.
This is not a significant difference as calculated by the authors of
this study. There were insufficient data provided for us to inde-
pendently confirm this. There were no deaths in either group.
One excluded study (Friis 1984) analysed separately a subgroup
of children in their trial who tested positive to RSV. This trial
randomised 150 children who had either fine crepitating rales or
pulmonary consolidation on chest radiograph to either antibiotics
(ampicillin) or no antibiotics. While this trial did not start by
selecting children with a clinical presentation of bronchiolitis, the
results of the subgroup analysis are relevant. In children who were
RSV positive, there was no significant difference found between
the antibiotic and no antibiotic groups for the outcomes of fever,
pulmonary symptoms, duration of hospital stay, otitis media or
chest radiograph findings.
The other excluded study (Mazumder 2006) found that children
with no antibiotics compared to those treated with antibiotics re-
covered over a similar period of time for the outcomes of chest in-
drawing, feeding, social smile, respiratory rate, wheeze and crepi-
tations. Tests of statistical significance were not applied to the data
from this study.
D I S C U S S I O N
Summary of main results
There have been very few randomised controlled trials conducted
to examine the use of antibiotics in bronchiolitis. The one study
justifying inclusion in this review did not support their use in
bronchiolitis. Specifically it found no significant difference in the
duration of the illness between the antibiotic and placebo arms of
the trial. One of the studies excluded by this review (Friis 1984),
examined this topic and also found no evidence for the use of
antibiotics in bronchiolitis. Specifically, Friis 1984 did not find
any significant difference between the use of antibiotics and no
antibiotics on the clinical course of bronchiolitis, fever, pulmonary
symptoms and chest radiograph appearances. The other excluded
study, Mazumder 2006, did not find any difference in symptom
outcome for childrenwith bronchiolitis treatedwith no antibiotics
or with antibiotics.
Overall completeness and applicability of
evidence
Clinicians may be concerned that if they do not use antibiotics in
a child presenting with a fever and clinical symptoms and signs
of bronchiolitis, they may be putting the child at risk of serious
complications such as pneumonia, septicaemia and death. It has
already been noted that children with this presentation are very
unlikely to have an occult bacteremia (Greenes 1999). This re-
view does not provide evidence supporting the use of antibiotics
in young children and babies presenting with bronchiolitis. The
results of this review should be treated with caution given that only
one randomised control trial was identified for inclusion.Methods
to reduce antibiotic use for bronchiolitis have been investigated.
Wilson 2002 found that a clinical pathway reduced inpatient an-
tibiotic use for bronchiolitis from 27% to 9%.
Children with serious illness requiring admission to intensive care
and especially those requiring ventilation may have higher rates
of bacterial co-infection possibly justifying the increased use of
antibiotics in this setting (Kyneber 2005; Thorburn 2006). There
have been no randomised controlled trials assessing the useful-
ness of antibiotics for bronchiolitis in an intensive care setting.
Bloomfield 2004 found that aside from intensive care admission
(2.9% with bacteraemia), children with a respiratory syncytial
virus (RSV) infection are more likely to be bacteraemic if they
have a nosocomial RSV infection (6.5% bacteraemia) or cyanotic
congenital heart disease (6.6% bacteraemia). The baseline rate of
bacteraemia in children with RSV bronchiolitis in this study was
0.6%.
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
This review found no evidence to support the use of antibiotics for
bronchiolitis. This result needs to be treated with caution given
only one randomised controlled trial justified inclusion.
Implications for research
It is unlikely that simple RCTs of antibiotics against placebo for
bronchiolitis will be undertaken in future. Research to identify a
possible small subgroup of patients presenting with bronchiolitis-
like symptoms who may benefit from antibiotics may be justified.
These might include those in intensive care; with nosocomially
acquired RSV; and with cyanotic congenital heart disease. Other-
wise, research may be better focused on determining the reasons
for clinicians to use antibiotics so readily for bronchiolitis, and
ways of reducing their anxiety, and therefore their use of antibi-
otics for bronchiolitis.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Field 1966
Methods Randomised controlled trial
Participants Babies
Interventions Ampicillin
Placebo
Outcomes Length of hospital stay
Symptoms (not specified)
Switch to treatment arm
Death
Notes
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Friis 1984 The patient selection criteria were fine crepitations or consolidation on chest radiograph which was not consistent
with our inclusion criteria of a purely clinical presentation of bronchiolitis
Mazumder 2006 Scored 3/11 on quality appraisal. The randomisationmethodwas considered inappropriate, there was no blinding,
no statistical analysis and no intention to treat analysis evident
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